Cerity Partners LLC Has $1.96 Million Stake in Encompass Health Co. (NYSE:EHC)

Cerity Partners LLC decreased its position in Encompass Health Co. (NYSE:EHC) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,433 shares of the company’s stock after selling 944 shares during the period. Cerity Partners LLC’s holdings in Encompass Health were worth $1,964,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Encompass Health by 1.2% in the third quarter. Vanguard Group Inc. now owns 9,653,180 shares of the company’s stock valued at $436,613,000 after purchasing an additional 111,745 shares in the last quarter. William Blair Investment Management LLC increased its stake in Encompass Health by 6.4% in the third quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock valued at $381,226,000 after purchasing an additional 342,512 shares in the last quarter. Invesco Ltd. increased its stake in Encompass Health by 22.3% in the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock valued at $266,914,000 after purchasing an additional 724,544 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Encompass Health by 4.4% in the first quarter. JPMorgan Chase & Co. now owns 3,144,147 shares of the company’s stock valued at $170,098,000 after purchasing an additional 133,885 shares in the last quarter. Finally, Baupost Group LLC MA increased its position in shares of Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock worth $213,330,000 after acquiring an additional 2,283,900 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Stock Up 0.8 %

EHC opened at $79.22 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of 22.83, a PEG ratio of 1.48 and a beta of 0.94. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $83.73. The company’s 50-day moving average price is $77.38 and its two-hundred day moving average price is $70.31.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.12. The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. As a group, equities analysts expect that Encompass Health Co. will post 3.96 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date was Thursday, March 28th. Encompass Health’s payout ratio is 17.29%.

Analyst Ratings Changes

Several research firms have recently commented on EHC. William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Stephens reissued an “overweight” rating and set a $85.00 target price on shares of Encompass Health in a research report on Tuesday, January 16th. Mizuho boosted their target price on shares of Encompass Health from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. Royal Bank of Canada reissued an “outperform” rating and set a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. Finally, Barclays upped their price objective on shares of Encompass Health from $95.00 to $101.00 and gave the stock an “overweight” rating in a research report on Thursday, March 28th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Encompass Health has a consensus rating of “Buy” and an average target price of $83.22.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.